Connect Biopharma Holdings Limited (Nasdaq: CNTB) announced its financial results for the fiscal year ended December 31, 2025, showcasing significant progress in its clinical pipeline and financial stability. The company reported cash, cash equivalents, and short-term investments totaling $44.3 million as of December 31, 2025, which, along with the recent $20.2 million equity financing, is expected to fund operations into the second half of 2027. The company highlighted positive topline data from its Phase 1 study of rademikibart, an innovative treatment for asthma and COPD, demonstrating rapid improvements in lung function. Additionally, results from a Phase 3 study of rademikibart in moderate-to-severe atopic dermatitis were presented at the 2026 American Academy of Dermatology Annual Meeting, indicating strong efficacy and safety profiles. The ongoing recruitment for Phase 2 Seabreeze STAT studies aims to further evaluate rademikibart's effectiveness in treating acute exacerbations in asthma and COPD, with topline data expected mid-2026. CEO Barry Quart emphasized the momentum gained in 2025 and the company's commitment to transforming care for inflammatory diseases.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.